288 related articles for article (PubMed ID: 34888493)
1. The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma.
Warricker F; Khakoo SI; Blunt MD
J Transl Genet Genom; 2021; 5():304-322. PubMed ID: 34888493
[TBL] [Abstract][Full Text] [Related]
2. The two-faces of NK cells in oncolytic virotherapy.
Marotel M; Hasim MS; Hagerman A; Ardolino M
Cytokine Growth Factor Rev; 2020 Dec; 56():59-68. PubMed ID: 32586674
[TBL] [Abstract][Full Text] [Related]
3. Sorting Out Pandora's Box: Discerning the Dynamic Roles of Liver Microenvironment in Oncolytic Virus Therapy for Hepatocellular Carcinoma.
Altomonte J; Ebert O
Front Oncol; 2014; 4():85. PubMed ID: 24795862
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in oncolytic virus therapy for hepatocellular carcinoma.
Zhu L; Lei Y; Huang J; An Y; Ren Y; Chen L; Zhao H; Zheng C
Front Oncol; 2023; 13():1172292. PubMed ID: 37182136
[TBL] [Abstract][Full Text] [Related]
5. Emerging role of Natural killer cells in oncolytic virotherapy.
Bhat R; Rommelaere J
Immunotargets Ther; 2015; 4():65-77. PubMed ID: 27471713
[TBL] [Abstract][Full Text] [Related]
6. Strategies to Optimise Oncolytic Viral Therapies: The Role of Natural Killer Cells.
Leung EYL; McNeish IA
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452316
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer.
van Vloten JP; Matuszewska K; Minow MAA; Minott JA; Santry LA; Pereira M; Stegelmeier AA; McAusland TM; Klafuric EM; Karimi K; Colasanti J; McFadden DG; Petrik JJ; Bridle BW; Wootton SK
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296558
[TBL] [Abstract][Full Text] [Related]
8. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
9. Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model.
Yu JL; Jang SR; Liu KY
Cells; 2023 Feb; 12(3):. PubMed ID: 36766849
[TBL] [Abstract][Full Text] [Related]
10. Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade.
Bozward AG; Warricker F; Oo YH; Khakoo SI
Front Immunol; 2021; 12():643310. PubMed ID: 33995362
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic virus treatment differentially affects the CD56
Wantoch M; Wilson EB; Droop AP; Phillips SL; Coffey M; El-Sherbiny YM; Holmes TD; Melcher AA; Wetherill LF; Cook GP
Immunology; 2022 May; 166(1):104-120. PubMed ID: 35156714
[TBL] [Abstract][Full Text] [Related]
12. Natural Killer Cells Recruitment in Oncolytic Virotherapy: A Mathematical Model.
Senekal NS; Mahasa KJ; Eladdadi A; de Pillis L; Ouifki R
Bull Math Biol; 2021 May; 83(7):75. PubMed ID: 34008149
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic parainfluenza virus combines with NK cells to mediate killing of infected and non-infected lung cancer cells within 3D spheroids: role of type I and type III interferon signaling.
Varudkar N; Oyer JL; Copik A; Parks GD
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172515
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells and natural killer cells: The road to a successful oncolytic virotherapy.
Ghasemi M; Abbasi L; Ghanbari Naeini L; Kokabian P; Nameh Goshay Fard N; Givtaj N
Front Immunol; 2022; 13():950079. PubMed ID: 36703982
[TBL] [Abstract][Full Text] [Related]
15. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
16. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO
J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307
[TBL] [Abstract][Full Text] [Related]
17. NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells.
Bhat R; Rommelaere J
BMC Cancer; 2013 Jul; 13():367. PubMed ID: 23902851
[TBL] [Abstract][Full Text] [Related]
18. NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer.
Leung EYL; Ennis DP; Kennedy PR; Hansell C; Dowson S; Farquharson M; Spiliopoulou P; Nautiyal J; McNamara S; Carlin LM; Fisher K; Davis DM; Graham G; McNeish IA
Mol Ther Oncolytics; 2020 Mar; 16():289-301. PubMed ID: 32195317
[TBL] [Abstract][Full Text] [Related]
19. Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes.
Shin S; Kim M; Lee SJ; Park KS; Lee CH
Cancer Genomics Proteomics; 2017; 14(5):349-362. PubMed ID: 28871002
[TBL] [Abstract][Full Text] [Related]
20. The emerging field of oncolytic virus-based cancer immunotherapy.
Ma R; Li Z; Chiocca EA; Caligiuri MA; Yu J
Trends Cancer; 2023 Feb; 9(2):122-139. PubMed ID: 36402738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
